Loading company
MDTMedtronic plc$130BA+Built from 10x Genomics, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes 10x Genomics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$62.02-1.4%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 6, 2026
Company outlook: revenue of $625M to $635M for Fiscal year 2026 — down 2.0% on a year earlier ($642.8M)
Just reported
From 10x Genomics's results release of November 5, 2026; its quarterly report has since been filed.
Actual
$150.7M
+1.1% y/y
-0.2% q/q
Guided
—
No guide given
Actual
-$0.15
Guided
—
No guide given
Actual
-$16.1M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade D
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 28 quarters of 10x Genomics, Inc.’s grade history. The other 26 go back to February 2020.
